aerpio
announces
enrollment
completed
phase
razuprotafib
glaucoma
trial
cincinnati
globe
newswire
aerpio
pharmaceuticals
aerpio
nasdaq
arpo
biopharmaceutical
company
focused
developing
compounds
activate
treat
ocular
diseases
diabetic
complications
well
indications
company
believes
activation
may
therapeutic
potential
including
acute
respiratory
distress
syndrome
ards
associated
infections
today
announced
completed
patient
enrollment
phase
trial
patients
elevated
intraocular
pressure
iop
associated
open
angle
glaucoma
oag
ocular
hypertension
oht
study
designed
evaluate
safety
efficacy
topical
ocular
formulation
razuprotafib
approximately
patients
followed
period
patients
must
undergo
washout
prior
randomization
patients
enrolled
trial
administered
baseline
latanoprost
ophthalmic
solution
randomized
fashion
receive
adjunctive
therapy
consisting
placebo
mg
ml
razuprotafib
mg
ml
razuprotafib
primary
endpoint
study
mean
diurnal
iop
days
razuprotafib
treated
groups
compared
latanoprost
monotherapy
group
remain
track
report
top
line
results
trial
fourth
quarter
said
kevin
peters
chief
scientific
officer
chief
medical
officer
aerpio
believe
razuprotafib
represent
attractive
adjunctive
therapy
glaucoma
patients
based
novel
mechanism
action
favorable
tolerability
profile
worldwide
rights
aerpio
pharmaceuticals
aerpio
pharmaceuticals
biopharmaceutical
company
focused
developing
compounds
activate
treat
ocular
diseases
diabetic
complications
well
indications
company
believes
activation
may
therapeutic
potential
including
acute
respiratory
distress
syndrome
ards
associated
infections
recently
published
mouse
human
genetic
data
implicate
angpt
pathway
maintenance
schlemm
canal
critical
component
conventional
outflow
tract
company
lead
compound
razuprotafib
formerly
small
molecule
inhibitor
vascular
endothelial
protein
tyrosine
phosphatase
developed
potential
treatment
open
angle
glaucoma
company
intends
investigate
therapeutic
potential
razuprotafib
indications
company
also
evaluating
development
options
humanized
monoclonal
antibody
therapeutic
potential
treatment
diabetic
vascular
complications
including
nephropathy
diabetic
macular
edema
dme
company
third
asset
bispecific
antibody
binds
vegf
designed
inhibit
vegf
activation
activate
bispecific
antibody
potential
improved
treatment
wet
macular
degeneration
dme
via
intravitreal
injection
finally
company
exclusively
called
small
molecule
inhibitor
hif
developed
exclusive
licensor
gossamer
bio
nasdaq
goss
information
please
visit
razuprotafib
formerly
known
razuprotafib
binds
inhibits
vascular
endothelial
protein
tyrosine
phosphatase
important
negative
regulator
decreased
activity
contributes
vascular
instability
many
diseases
including
diabetes
recently
shown
contribute
development
increased
iop
glaucoma
razuprotafib
activates
receptor
irrespective
extracellular
levels
binding
ligands
agonist
antagonist
may
efficient
pharmacologic
approach
maintain
normal
activation
aerpio
studying
topical
ocular
formulation
razuprotafib
open
angle
glaucoma
exploring
utility
subcutaneous
razuprotafib
diabetic
complications
including
diabetic
nephropathy
addition
subcutaneous
formulation
razuprotafib
explored
therapeutic
potential
treating
preventing
ards
associated
forward
looking
statements
press
release
contains
statements
statements
press
release
purely
historical
statements
statements
include
among
things
company
product
candidates
including
razuprotafib
bispecific
antibody
asset
clinical
development
plan
therefor
therapeutic
potential
thereof
company
plans
expectations
respect
razuprotafib
development
therefor
therapeutic
potential
thereof
addressing
intended
benefits
company
collaboration
gossamer
bio
including
continued
development
milestone
royalty
payments
related
collaboration
actual
results
could
differ
projected
statements
due
several
risk
factors
factors
include
among
others
continued
development
maintaining
deriving
intended
benefits
company
collaboration
gossamer
bio
ability
continue
develop
razuprotafib
product
candidates
including
indications
related
inherent
uncertainties
associated
drug
development
process
including
uncertainties
regulatory
interactions
design
planned
future
clinical
trials
commencing
clinical
trials
enrollment
patients
clinical
trials
obtaining
necessary
regulatory
clearances
order
commence
conduct
planned
future
clinical
trials
impact
ongoing
pandemic
company
business
operations
including
research
development
efforts
ability
company
commence
conduct
complete
planned
clinical
activities
competition
industry
company
operates
overall
market
conditions
additional
factors
set
forth
annual
report
form
year
ended
december
updated
subsequent
quarterly
reports
form
subsequent
filings
sec
statements
made
date
press
release
company
assumes
obligation
update
statements
update
reasons
actual
results
could
differ
projected
statements
except
required
law
investors
consult
information
set
forth
herein
also
refer
risk
factor
disclosure
set
forth
reports
documents
company
files
sec
available
contacts
investors
media
aerpio
pharmaceuticals
joseph
gardner
president
founder
jgardner
gina
marek
vp
finance
gmarek
investors
irina
koffler
lifesci
advisors
ikoffler
source
aerpio
pharmaceuticals
inc
